secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELITE PHARMACEUTICALS INC /NV/ (ELTP)
CIK:        0001053369
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001493152-22-031356
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elite Pharmaceuticals and Lannett terminate Vigabatrin agreement; marketing rights return to Elite
--------------------------------------------------------------------------------

- Joint termination of License, Supply and Distribution Agreement for Vigabatrin effective Nov 9, 2022.
- All marketing rights for Vigabatrin revert to Elite Pharmaceuticals.
- Agreement was with Lannett Company, Inc.; no further details on reason or financial impact.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053369/000149315222031356/0001493152-22-031356-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053369/000149315222031356/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-031356

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer